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Abstract 
 
Duchenne Muscular Dystrophy (DMD) is caused by mutations in the dystrophin gene leading to dystrophin deficiency, muscle fiber 
degeneration and progressive fibrotic replacement of muscles. Givinostat, a histone deacetylase (HDAC) inhibitor, significantly reduced fibrosis 
and promoted compensatory muscle regeneration in mdx mice. This study was conducted to evaluate whether the beneficial histological effects 
of Givinostat could be extended to DMD boys. Twenty ambulant DMD boys aged 7 to <11 years on stable corticosteroid treatment were 
enrolled in the study and treated for ≥12 months with Givinostat. A muscle biopsy was collected at the beginning and at the end of treatment to 
evaluate the amount of muscle and fibrotic tissue. Histological effects were the primary objectives of the study. Treatment with Givinostat 
significantly increased the fraction of muscle tissue in the biopsies and reduced the amount of fibrotic tissue. It also substantially reduced tissue 
necrosis and fatty replacement. Overall the drug was safe and tolerated. Improvement in functional tests was not observed in this study, but the 
sample size of the study was not sufficient to draw definitive conclusions. This study showed that treatment with Givinostat for more than 1 
year significantly counteracted histological disease progression in ambulant DMD boys aged 7 to 10 years. 
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1. Introduction 
 
Duchenne Muscular Dystrophy (DMD) is the most common 
muscular dystrophy in childhood  [1]. The disease is caused by 
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mutations in the dystrophin gene, leading to dystrophin 
deficiency and subsequent cell membrane instability. This 
instability determines uncontrolled calcium influx, 
inflammation, necrosis, and replacement of muscle with 
fibrotic tissue and fat, which leads to severe muscle wasting 
and weakness. 
 
Pharmacological blockade of the histone deacetylase activity, 
which is constitutively active in DMD muscles  [2] by 
 
. 
 
HDAC inhibitors (HDACi), prevents fibrosis and promotes 
compensatory regeneration in the mdx mouse, a model of 
DMD  [3,4]. 
 
Givinostat (aka ITF2357) is a potent HDACi currently 
being developed for the treatment of DMD. In mdx mice  [3], 
Givinostat dose and concentration dependently increased the 
cross-sectional area of myofibers, decreased the cellular 
inflammatory infiltrate and prevented the formation of fibrotic 
scars. These findings strongly suggested that in this DMD 
animal model Givinostat was able to inhibit all the processes 
which determine muscle fibrotic substitution (inflammation, 
necrosis, fatty replacement and fibrosis) and to stimulate 
muscle regeneration with the formation of larger muscle fibers 
and overall more muscle tissue. Results also suggested that 
exposures of Givinostat of 300 ng*h/mL are required to exert 
the beneficial effect. 
 
To evaluate the potential of Givinostat as a treatment for 
DMD, we conducted the study summarized in this manuscript. 
The primary objective of this study was to confirm also in 
humans that Givinostat can counteract the histological signs 
of the disease. 
 
2. Methods 
 
2.1. Patients 
 
Twenty boys aged 7 to <11 years with an 
immunohistochemical and molecular diagnosis of DMD were 
enrolled in this study after an informed consent form was 
signed by a parent/guardian and child had assented to be in the 
study (if applicable). Boys were on a stable dose of systemic 
corticosteroids for at least six months and were able to 
complete the two screening 6 minute walk tests (6MWT) with 
a minimal distance of at least 250 meters each with the results 
of these tests within ± 30 meters of each other. Exclusion 
criteria were aimed at avoiding confounding factors from 
other potentially active treatments, and at recruiting boys 
without significant co-morbidities and without clinical 
alterations that could be worsened by Givinostat, e.g. low 
platelet counts. Detailed inclusion/exclusion criteria are 
summarized in the Supplementary Information. 
 
2.2. Design 
 
This was an open label two-part, phase 2 study. The 
primary study objective was the evaluation of the histological 
effects of Givinostat comparing baseline and end of treatment 
muscle biopsies (brachial biceps). Secondary objectives of the 
study were safety and tolerability, and functional assessments 
(6MWT, North Star Ambulatory Assessment (NSAA) and 
Performance of Upper Limb (PUL)). 
 
 Fig. 1 summarizes the study design. Part 1 was a dose 
escalation study. Boys were asked to return to sites every 
week for physical examination, vital signs, ECG, laboratory 
tests, AEs collection, drug dispensing and PK sampling (only 
at week 2). 
 
All the boys who completed Part 1 entered Part 2. One boy 
entered the study directly in Part 2. Boys visited their study 
site at months 1, 2, 3, 4.5, 6, 7.5, 9, 10.5 and 12 of Part 2 for 
 
physical examination, vital signs, ECG, laboratory tests, AEs 
collection, drug dispensing and PK sampling (only at month 12). 
6MWT, NSAA, and PUL were evaluated at screening, start of 
part 2, and at months 3, 6 and 12. Echocardiogram and 
spirometry were conducted at screening and at the end of part 2. 
 
2.3. Standard protocol approvals, registrations and patient 
consents 
 
The study was sponsored by Italfarmaco S.p.A. (Milan, 
Italy), performed in compliance with Good Clinical Practice 
and the Declaration of Helsinki and it was registered 
(Identifier NCT01761292) at  www.Clinicaltrials.gov. The 
study was approved by the local Ethics Committees and 
authorized by the Competent Authority of Italy. A parent or 
guardian of the participants provided informed written consent 
and each subject provided written assent before participation. 
 
2.4. Treatments 
 
All boys were treated with Givinostat. During part 1 the 
dose was escalated from 25 mg BID to 50 mg BID and then 
reduced to 37.5 mg BID dose. During part 2 all boys were 
started on the 37.5 mg BID; seven completed the study on this 
dose and twelve reduced the dose to 25 mg BID (see below 
for details). All boys continued the steroid treatment regimen 
they were on at screening. 
 
2.5. Endpoints 
 
Histology: the primary endpoint was the change in 
histology comparing the brachial biceps biopsies before and 
after ≥12 months of treatment with Givinostat. The 
histological parameters assessed were: muscle fiber area 
fraction (MFAF), cross-sectional area (CSA), necrosis, 
hypercontracted (hyaline) fibers, fatty replacement and 
fibrosis (total, endomysial, perimysial). Details on muscle 
biopsy collection, preparation and histological assessments are 
provided in the Supplementary Information. 
 
Muscle Function Tests: change in 6MWT, NSAA and PUL 
after treatment with Givinostat were secondary endpoints. Details 
on these function tests were reported previously  [5–7]. 
 
Safety and tolerability were assessed by AEs collection, 
laboratory tests, physical examination, vital signs, ECG, 
echocardiogram and spirometry. The following laboratory 
tests were performed: hematology, total bilirubin, alkaline 
phosphatase, amylase, ALT, AST, LDH, C-reactive protein, 
creatine kinase, total protein, albumin, uric acid, sodium, 
potassium, chloride, calcium, glucose, creatinine, BUN, and 
CPK, creatinine clearance, and urinalysis. Laboratory tests 
were conducted at local laboratories. 
 
2.6. Statistical analysis 
 
Based on the results reported in the Desguerre publication  [8], 
a sample size of 20 boys completing the study provided a 90% 
power (at a 2-sided alpha level of 5%) to detect at least a 25% 
relative increase in MFAF between pre- and post-treatment using 
a paired t-test and assuming a normal distribution. 
 The histological parameters were analyzed on all boys who 
completed the study, received at least 80% of the Givinostat 
dose in Part 2, had one baseline and one post-baseline 
assessment of biopsies, and had no major protocol violations. 
The ITT population, including all boys enrolled in Part 1 or 
Part 2 of the study, was used for all the other assessments. 
 
The statistical significance of the change from baseline to 
the end of the study was tested by paired T-test. Normality 
assumptions were confirmed by the Shapiro–Wilk test of 
normality. All statistical tests were performed using a two-
tailed 5% significance level. 
 
Givinostat effect on fiber size was evaluated considering the 
distribution of CSA before treatment (PRE) and at the end of the 
study (POST). For each individual, PRE and POST CSA values 
were normalized to the maximum PRE CSA value of that 
individual. The pooled PRE and POST log-CSA values 
histograms obtained after normalization and logarithmic 
transformation were inspected to ascertain a possible shift 
towards higher fiber size values in the POST distribution. In 
particular, a common shape underlying the PRE and POST 
distributions, differing just by a shift S in terms of fiber size, was 
considered. The common shape was described as a 2-component 
Gaussian mixture, whose parameters were estimated by the 
Expectation–Maximization method. The value 
 
of the shift S quantifies the effect of Givinostat on a generic 
muscle fiber, whose size, after treatment, results K = exp(S) 
times larger than the baseline value. 
 
3. Results 
 
The baseline characteristics of the 20 boys are summarized in  
Fig. 1. In Part 1, four boys started at the 25 mg BID dose, eight at 
the 50 mg BID dose and another seven boys at the 37.5 mg BID 
dose. Overall, Part 1 lasted 2 months. One of the 19 boys enrolled 
in Part 1 was discontinued from the study as he reached a 
stopping rule (platelet counts <50 × 109/L) while on treatment 
with Givinostat 50 mg BID. Another boy treated with Givinostat 
50 mg BID reached a stopping rule of temporary treatment 
suspension (platelet counts <75 × 109/L but >50 × 109/L). As a 
result and according to the predefined rules to declare the 
Maximum Tolerated Dose the dose of 50 mg BID was considered 
not tolerated. The remaining 18 boys and one other boy entered 
in Part 2. The dose of 37.5 mg BID was considered the Maximum 
Tolerated Dose and recommended for Part 2. At the beginning of 
Part 2 some boys treated at 37.5 mg BID had platelet reduction 
below the LLN but never <75 × 109/L (temporary stopping 
criterion). Therefore, the protocol was amended to require that 
platelet counts be assessed ≥every 2 weeks in the first 2 months 
of therapy 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Study design and patient demography. Overall, Part 1 lasted 2 months, while part 2 lasted 12 months. 
   
 
  
 
Table 1         
 
Histological parameters at baseline and end of study and absolute and relative change.   
 
      
 
 Baseline  End of Study Absolute Change Relative Change 
 
 Mean ± SD Mean ± SD Mean (95% CI)   
 
        
MFAF (%) 51.00± 9.61 64.91 ± 8.35 13.91 29.1% 
 
     (11.57, 16.25; p < 0.0001)   
 
     • Deletions:13.25(10.16, 16.33; p < 0.0001) • Deletions:27.1% 
 
     • Duplications:11.42(5.30, 17.54; p = 0.0095) • Duplications:20.0% 
 
     • Point Mutations:17.08(10.15, 24.00; p = 0.0024) • Point Mutations:39.6% 
 
CSA (μm2) * 1191.09± 400.98 2056.36 ± 781.39 865.27 ± 555.35 77.7% 
 
   (p < 0.0001)   
 
Hypercontracted Fibers 1.98± 0.71 0.77 ± 0.54 −1.20 −60.4% 
 
   (−1.53, −0.87; p < 0.0001)   
 
Total Fibrosis (%) 46.13± 9.61 33.49 ± 8.24 −12.64 −27.4% 
 
   (−14.95, −10.33; p < 0.0001)   
 
Endomysial Fibrosis (%) 22.66± 6.51 17.60 ± 3.69 −5.06 −18.48% 
 
   (−8.17, −1.95; p= 0.0032)   
 
Perimysial Fibrosis (%) 23.47± 8.66 15.88 ± 5.56 −7.59 −27.3% 
 
   (−10.81, −4.36; p= 0.0001)   
 
Necrosis (%) 1.98± 0.73 1.02 ± 0.32 −0.96 −43.5% 
 
   (−1.28, −0.65; p < 0.0001)   
 
Fatty Replacement (%) 0.89± 0.70 0.58 ± 0.60 −0.30 −37.5% 
 
     (−0.44, −0.17; p= 0.0002)   
 
* Absolute change is mean ± SD. 
 
 
at 37.5 mg BID and that the dose be lowered to 25 mg BID if 
persistent platelet counts ≤150 × 109/L were observed. 
Givinostat dose was maintained at 37.5 mg BID in 7 boys and 
reduced to 25 mg BID in 12. All 19 boys who entered Part 2 
completed that part of the study. End of study biopsy could 
not be evaluated in one boy due to poor conditions of the 
tissue collected. 
 
All biopsies showed a negative immunoreaction for 
dystrophin at baseline and end of study.  Table 1 and Tables 
S1–S2 summarize the histological results (Fig. S2 provides 
examples of histological results). At baseline on average 46% 
of the tissue samples were occupied by fibrosis, and 51% by 
muscle. At the end of Part 2, there was a significant reduction 
of necrotic and hyper contracted fiber number, fat tissue 
replacement, and endomysial and perimysial fibrosis. MFAF 
increased due to a homogeneous increment of the CSA value 
of all fibers. Mean CSA increased by 77.7%. As shown in  
Fig. 2, the distribution of log-transformed CSA had a similar 
shape before and after treatment with Givinostat. Treatment 
with Givinostat shifted the distribution to the right, indicating 
a multiplicative increase in fiber size by a factor K = exp(S) = 
1.70 (p ≤ 0.001). K values were significantly larger in boys 
treated with 37.5 mg BID throughout Part 2 of the study 
compared to those who switched to the 25 mg BID dose 
(Mean ± SD 37.5 mg BID (N = 7) = 2.11 ± 0.52; Mean ± SD 
25 mg BID (N = 12) = 1.61 ± 0.37, p < 0.05). Histological 
parameters did not correlate with either age or steroid 
treatment duration either at baseline or at the end of Part 2 
(age: R = −0.18 to 0.43, NS; steroid duration: R −0.16 to 0.34, 
NS). 
 
Three serious AEs were reported during the study (platelet 
reduction, rhabdomyolysis during muscle biopsy anesthesia, 
tibioperoneal fracture). Only the Platelet reduction was 
considered drug related (dose: 50 mg BID) and led to study 
 
 
discontinuation. All AEs were mild to moderate in intensity 
except for the aforementioned serious AEs and a platelet and 
neutrophil decrease (drug related) in Part 2.  Table 2 
summarizes the drug related AEs reported in Part 1 ( Table 
2A) and Part 2 ( Table 2B) by more than 1 boy. 
 
Platelet decrease and diarrhea were the most frequent AEs in 
the study. In Part 1, white blood cell decreased and most of the 
platelet decreased was reported only at the 50 mg BID dose. In 
Part 2, platelet decrease has been reported more frequently, with 
the 37.5 mg BID dose (63.2% vs 41.7%). Givinostat treatment 
was not associated to any other clinically significant laboratory 
abnormality. Similarly, vital signs, FEV1, FVC, FEV1/FVC, PEF 
and ECGs were not significantly altered. 
 
 Table 3 reports the results in the functional tests. One child 
could not complete the 6MWT at month 12 due to a 
tibioperoneal fracture at month 6. MFAF (directly) and total 
fibrosis (indirectly) correlated with the 6MWT at baseline and 
end of study. MFAF and Total Fibrosis correlated also with 
NSAA total score at baseline and with time to rise from floor 
at the end of the study (Table S3). 
 
Pharmacokinetic analyses indicated that following oral BID 
administration givinostat plasma exposures were dose-
proportional. Cmax was observed at 2 to 4 hours post-dosing 
(median) at all doses administered. At all dose levels, the 
variability of plasma PK parameters was limited. Givinostat was 
at steady-state following 7 days of administration. Analysis of the 
accumulation ratios suggested a slight reduction (approximately 
30%) at the end of the study compared to the results obtained 
following one week of treatment. 
 
4. Discussion 
 
While other treatments have previously shown to partially 
restore dystrophin  [9,10], this is the first time that a 
pharmacological treatment was shown to produce beneficial 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. Comparison of the estimated distributions of normalized log-CSA values measured in the biopsies before treatment (PRE) and at the end of part 2 (POST). 
In the inset, the estimated distributions are superimposed on the pooled histograms. 
 
 
histological effects in muscles of DMD patients, though a 
functional benefit could not be definitively assessed due to the 
small sample size. Previous studies on muscle biopsies in DMD  
[8,11] suggest that reductions in necrosis, fatty replacement and 
fibrosis and increase in muscle fiber area fraction do not occur 
with disease progression in boys seven to ten years of age. This is 
also supported by recent data with MRI and MRS that show a 
progressive tissue damage in boys with DMD five years and 
 
 
Table 2 
 
 
older  [12]. Thus these histological effects are attributable to 
Givinostat. The role of Givinostat treatment is further supported 
by the lack of correlation between MFAF and total fibrosis and 
either age or steroid treatment duration. Since Givinostat acts on 
the pathogenetic events downstream of the genetic defects, 
Givinostat is potentially a treatment for the whole DMD 
population. The similar results in boys with deletions, 
duplications or point mutations support this conclusion. 
 
Drug related Treatment Emergent Adverse Events (TEAEs) that occurred in more than 1 patient during the Part 1 of the study (A) and during the Part 2 of the study 
 
(B). 
 
A 25.0 mg BID 37.5 mg BID  50.0 mg BID Overall 
 (N = 4)  (N = 7)  (N = 12) (N = 19) 
          
Number (%) of Patients with drug related TEAEs 3 (75.0%)  6 (85.7%)  12 (100%) 18 (94.7%) 
Abdominal pain 0 (0.0%)  2 (28.6%)  1 (8.3%) 3 (15.8%) 
Diarrhea 2 (50.0%)  3 (42.9%)  5 (41.7%) 8 (42.1%) 
Feces soft 0 (0.0%)  1 (14.3%)  1 (8.3%) 2 (10.5%) 
Platelet decreased 0 (0.0%)  1 (14.3%)  7 (58.3%) 8 (42.1%) 
White blood cell count decreased 0 (0.0%)  0 (0.0%)  4 (33.3%) 4 (21.1%) 
Rash 1 (25.0%)  0 (0.0%)  1 (8.3%) 2 (10.5%) 
       
B  25.0 mg BID   37.5 mg BID Overall 
  (N = 12)   (N = 19)  (N = 19) 
          
Number (%) of Patients with drug related TEAEs  9 (75.0%)   18 (94.7%) 18 (94.7%) 
Abdominal pain  0 (0.0%)   5 (26.3%) 5 (26.3%) 
Diarrhea  6 (50.0%)   9 (47.4%) 11 (57.9%) 
Vomiting  1 (8.3%)   2 (10.5%) 3 (15.8%) 
Platelet decreased  5 (41.7%)   12 (63.2%) 12 (63.2%) 
Decreased appetite  2 (16.7%)   4 (21.1%) 6 (31.6%) 
Headache  1 (8.3%)   1 (5.3%)  2 (10.5%) 
           
 
 
 
 
Table 3 
 
Results of Functional Tests at each study visit (Mean (SD, N)) during Part 2. 
 
 6MWT Distance NSAA Rise from floor PUL 
 (meters) Total Score (seconds) Total Score 
     
Baseline 453.0 28.1 4.43 71.7 
 (62.23, 19) (5.13, 19) (1.41, 18) (2.40, 19) 
Month 0 450.9 28.4 4.87 71.9 
 (58.00, 19) (4.46, 19) (1.57, 18) (2.61, 18) 
Month 3 416.6 27.6 6.75 72.2 
 (86.13, 19) (6.16, 19) (8.42, 19) (2.32, 19) 
Month 6 421.9 27.3 6.87 72.4 
 (73.96, 19) (5.58, 19) (8.22, 19) (1.57, 19) 
Month 12 432.2 26.2 5.04 71.6 
 (63.60, 18 *) (6.10, 18 *) (2.09, 17 *) (2.81, 19) 
     
 
* A patient could not perform the 6MWT and was excluded from the NSAA 
and Rise from floor analysis relevant to month 12 because he fractured his 
tibia and fibula just after the 6-month functional assessments. 
 
 
The mechanism of action at the basis of these histological 
changes induced by Givinostat is still not fully elucidated. 
However, it is already evident that Givinostat treatment is 
followed by a homogeneous increase in muscle fibers size 
( Fig. 2). Although follistatin and myostatin levels and/or their 
downstream effects could not be assessed in the muscle 
biopsies in this study, HDACi have been previously shown to 
increase follistatin translation  [4,13]. Follistatin down 
regulates myostatin a major inhibitor of muscle fibers 
regeneration  [14–16] and in nature myostatin defects are 
accompanied by large muscle mass. Future studies will need 
to clarify the role of follistatin translation in the effects on 
muscle fiber size observed with Givinostat. 
 
The other key objective of this study was to confirm that doses 
determining a significant histological effect were also tolerated in 
boys with DMD. Platelet reductions and gastrointestinal AEs 
have been the most frequent AEs in this study. Platelet reduction 
has been observed with all HDACi tested so far including 
Givinostat and it is considered related to their pharmacological 
effect  [17]. In this study, platelet reduction, which met 
predefined stopping rules, were observed only at 50 mg BID, a 
dose considered not tolerable. In Part 2, platelet counts remained 
within the normal range after treatment with 37.5 mg BID in 7 
boys, while in other 12 the dose was lowered to 25 mg BID to 
maintain platelet counts within the normal range. The decision to 
lower the dose was made even if no clinical manifestation of low 
platelet counts (e.g. hemorrhage, petechiae, etc.) was observed. 
 
In this study we wanted to maintain exposures to Givinostat as 
high as possible to maximize the chances of seeing a histological 
benefit. Using a starting dose of 37.5 mg BID and applying the 
dose adjustment rules described in the Results section met the 
objective of maintaining high exposures without abnormal 
platelet counts. However, the dose was reduced to 25 mg BID in 
2/3 of patients. Significant histological improvements were 
observed in all children in Part 2, regardless of their dose. 
However, CSA increased significantly more in boys treated at the 
highest dose throughout part 2. As CSA fibers enlargement 
appears to be a key event in the Givinostat effect, this result 
suggests that even if exposures 
 
obtained after the 25 mg BID dose are efficacious, there is a 
potential benefit in trying to maintain Givinostat exposures as 
high as possible. Further studies will confirm if larger 
Givinostat exposures are beneficial and if the dose adjustment 
rules adopted in this study will allow maintaining platelet 
counts stable and within normal ranges also in larger cohorts 
of DMD patients. 
 
Diarrhea was frequently reported in this study, but was 
mild or moderate, never required treatment adjustments and 
never led to drug discontinuation, suggesting that this AE is 
quite manageable. 
 
This study was not designed to assess efficacy and functional 
tests were performed to evaluate possible negative effects on 
muscle function. The changes in the function tests were relatively 
small and similar to those expected in a DMD population similar 
to the one in this study  [18–20]. Because of the small sample 
size and of the lack of a control group, no further considerations 
can be made on the Givinostat effects on muscle function. The 
significant correlation between the MFAF and total fibrosis and 
most of the functional tests, however, suggests that the 
histological improvements observed with Givinostat may 
eventually lead to a functional benefit. 
 
This study has challenges and limitations. Muscle biopsies are 
always a challenge. A very tight control was maintained 
throughout the study on muscle biopsy collection, transport, 
processing and analysis. As a result only 1 biopsy was considered 
not suitable for analysis. In our study the histological and 
morphological analysis was performed to the best standards 
following well documented identification criteria typical of DMD 
skeletal muscle alterations  [21], and morphological analysis was 
carried out using MetaMorph, a recognized reliable software. In 
fact, our baseline results are in line with the results previously 
reported  [8,22]. This study did not include a control group, since 
it was not considered ethical to have a group of boys on placebo 
undergoing 2 biopsies without any chance of a potential treatment 
benefit. However, as no histological improvements are expected 
in a group of DMD boys aged seven to ten years, the significant 
histological results obtained in this study are not affected by the 
lack of a control group. Even if the patient number was small, the 
study was fully powered to show an increase in MFAF at least as 
large as the one observed in the preclinical study  [3]. 
 
In conclusion, this study shows that administration of 
Givinostat for more than one year significantly counteracts 
histological disease progression in ambulant DMD boys aged 
seven to ten years. These results support further development 
of Givinostat in DMD. 
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